drugset / Trial / NCT01387464

Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery

NCT01387464

Phase 2 Completed 60 enrolled Sun Pharmaceutical Industries, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the aqueous humor concentration of bromfenac sodium in subjects administered multiple topical ocular doses of ISV-303 or Bromday™ QD prior to routine cataract surgery.

Timeline

Start
2011-07
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Bromfenac Other / unclassified 0.075 % Topical
Subject Bromfenac Other / unclassified 0.09 % Topical

Indications